The purpose of this study is to monitor ongoing safety in participants with ulcerative colitis (UC) and Crohn's disease (CD) and to provide access to vedolizumab for qualifying participants who, in the opinion of the investigator, continue to derive benefit from vedolizumab and for whom continued treatment with vedolizumab is desired because there is no other comparable product available or the participant may be expected to develop worsening of disease if they were to modify treatment.
The drug being used in this study is called vedolizumab, which is being used to treat people who have ulcerative colitis or Crohn's disease. This study will monitor ongoing safety in the people who take vedolizumab. Participants who have successfully completed the participation in qualifying vedolizumab clinical studies will be enrolled and assigned to receive: • Vedolizumab 300 mg All participants will receive an intravenous (IV) infusion once every 8 weeks until vedolizumab is available through commercial channels, including reimbursement, for the participant's clinical scenario, or until participant withdrawal, whichever comes first. (Per MM approval, dosing regimen may be modified) This multicenter trial will be conducted worldwide. Participants will make multiple visits to the clinic and a final visit at 18 weeks after receiving the last dose of study infusion of vedolizumab for a safety follow-up assessment.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
331
Vedolizumab IV infusion
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the study drug. A SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires participant hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect or is an important medical event. Percentages are rounded off to the nearest decimal point.
Time frame: From first dose of study drug in this XAP study through 18 weeks after the last dose of study drug (up to 6.3 years)
Percentage of Participants With Adverse Events of Special Interest (AESIs)
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the study drug. AESIs included serious infections (opportunistic infections, such as progressive multifocal leukoencephalopathy \[PML\]), malignancies, liver injury, infusion-related hypersensitivity reactions, and injection site reactions. Percentages are rounded off to the nearest decimal point.
Time frame: From first dose of study drug in this XAP study through 18 weeks after the last dose of study drug (up to 6.3 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The Canberra Hospital
Garran, Australian Capital Territory, Australia
Western Hospital
Footscray, Victoria, Australia
Cabrini Medical Centre
Malvern, Victoria, Australia
Box Hill Hospital
Box Hill, Australia
Royal Brisbane & Women's Hospital
Herston, Australia
Fiona Stanley Hospital
Murdoch, Australia
Multiprofile Hospital For Active Treatment Ruse
Rousse, Bulgaria
City Clinic University Multiprofile Hospital for Active Treatment EOOD
Sofia, Bulgaria
Karlovarska krajska nemocnice a.s.
Karlovy Vary, Karlovarsk Kraj, Czechia
Hepato-Gastroenterologie HK, s. r. o.
Hradec Králové, Czechia
...and 68 more locations